Porter D C, Ansardi D C, Choi W S, Morrow C D
Department of Microbiology, University of Alabama, Birmingham 35294-0007.
J Virol. 1993 Jul;67(7):3712-9. doi: 10.1128/JVI.67.7.3712-3719.1993.
The use of recombinant viruses for the expression of a wide array of foreign proteins has become commonplace during the last few years. Recently, we have described the construction and characterization of chimeric human immunodeficiency virus type 1 (HIV-1)-poliovirus genomes in which the gag and pol genes of HIV-1 have been substituted for the VP2 and VP3 capsid genes of the P1 capsid precursor region of poliovirus. Transfection of these RNAs into tissue culture cells results in replication of the RNA genome and expression of HIV-1-P1 fusion proteins (W. S. Choi, R. Pal-Ghosh, and C. D. Morrow, J. Virol. 65:2875-2883, 1991). Here we report on the encapsidation and amplification of the minireplicons to obtain sufficient quantities for biological characterization. To do this, HIV-1-poliovirus minireplicon genomes containing the gag or pol gene were transfected into cells previously infected with a recombinant vaccinia virus (VV-P1) which expresses the poliovirus capsid precursor protein, P1 (D. C. Ansardi, D. C. Porter, and C. D. Morrow, J. Virol. 65:2088-2092, 1991). The chimeric minireplicons replicated and expressed the appropriate HIV-1-P1 fusion proteins as determined by immunoprecipitation with HIV-1-specific antibodies. The encapsidated genomes were isolated by ultracentrifugation. Reinfection of cells with the encapsidated chimeric RNA genomes resulted in expression of the HIV-1-Gag-P1 or HIV-1-Pol-P1 fusion protein. Serial passaging of the encapsidated chimeric HIV-1-poliovirus genomes was accomplished by coinfecting cells with the encapsidated minireplicons and VV-P1, resulting in stocks of the encapsidated minireplicons. Northern (RNA) blot analysis of passaged material revealed that no detectable deletions of the chimeric genomes occurred during 14 serial passages. Infection of cells by the encapsidated minireplicons was blocked by antipoliovirus antibodies. Coinfection of cells with encapsidated minireplicons and type 1 Sabin poliovirus resulted in encapsidation of the chimeric genomes by wild-type poliovirus as measured by immunoprecipitation of the HIV-1-P1 fusion proteins with HIV-1-specific antibodies. The results of this study demonstrate the encapsidation of poliovirus minireplicons which express foreign proteins and point to the future use of this system as a potential vaccine vector.
在过去几年中,使用重组病毒表达多种外源蛋白已变得很常见。最近,我们描述了嵌合型1型人类免疫缺陷病毒(HIV-1)-脊髓灰质炎病毒基因组的构建和特性,其中HIV-1的gag和pol基因已被脊髓灰质炎病毒P1衣壳前体区域的VP2和VP3衣壳基因所取代。将这些RNA转染到组织培养细胞中会导致RNA基因组的复制以及HIV-1-P1融合蛋白的表达(W. S. Choi、R. Pal-Ghosh和C. D. Morrow,《病毒学杂志》65:2875 - 2883,1991年)。在此我们报告了微型复制子的包装和扩增情况,以获得足够量用于生物学特性分析。为此,将含有gag或pol基因的HIV-1-脊髓灰质炎病毒微型复制子基因组转染到先前感染了表达脊髓灰质炎病毒衣壳前体蛋白P1的重组痘苗病毒(VV-P1)的细胞中(D. C. Ansardi、D. C. Porter和C. D. Morrow,《病毒学杂志》65:2088 - 2092,1991年)。通过用HIV-1特异性抗体进行免疫沉淀测定,嵌合微型复制子进行了复制并表达了相应的HIV-1-P1融合蛋白。通过超速离心分离出包装好的基因组。用包装好的嵌合RNA基因组再次感染细胞导致HIV-1-Gag-P1或HIV-1-Pol-P1融合蛋白的表达。通过将包装好的微型复制子与VV-P1共同感染细胞来完成包装好的嵌合HIV-1-脊髓灰质炎病毒基因组的连续传代,从而获得包装好的微型复制子储备。对传代材料进行的Northern(RNA)印迹分析表明,在14次连续传代过程中未检测到嵌合基因组的缺失。抗脊髓灰质炎病毒抗体可阻断包装好的微型复制子对细胞的感染。用包装好的微型复制子与1型Sabin脊髓灰质炎病毒共同感染细胞,通过用HIV-1特异性抗体对HIV-1-P1融合蛋白进行免疫沉淀测定,结果表明野生型脊髓灰质炎病毒对嵌合基因组进行了包装。本研究结果证明了表达外源蛋白的脊髓灰质炎病毒微型复制子的包装,并指出该系统未来可作为一种潜在的疫苗载体。